Osteoarthritis in the KneeNCT03679507
The Effect of Low Intensity Ultrasound Therapy on Chronic Pain Due to Osteoarthritis of the Knee.
A study testing Low Intensity Ultrasound Therapy and Enhancing CBD oil penetration into joints by sonophresis in people with Osteoarthritis in the Knee, run by Dr. Kevin Rod at 1 site in Canada.
Trial summary
To evaluate a new, low intensity ultrasound device in the treatment of chronic pain due to osteoarthritis in the knee. Enhancing CBD oil penetration into joints by sonophoresis. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Osteoarthritis in the Knee
- What is being tested?
- Low Intensity Ultrasound Therapy and Enhancing CBD oil penetration into joints by sonophresis
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 84 participants
- Where
- 1 siteCanada
- Study dates
- 15 Jun 2019to Dec 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Osteo-arthritis of knee joint diagnosed through X-Ray evaluation
- Moderate or sever level of pain due to knee osteoarthritis and no other known reason
- Male of Female patients of 18 to 85 years old
- Pain interfering with activities of daily life
Who cannot join
- Cancer pain or any other concurrent cancerous condition
- History of Knee replacement surgery in the study joint
- Local infection or any kind of inflammatory or allergic skin lesion
- Rheumatoid arthritis
- Mobility disorders or not being able to walk
Trial locations and contacts
1 site in 1 country.
About this study
To evaluate a new, low intensity ultrasound device in the treatment of chronic pain due to osteoarthritis in the knee.
Enhancing CBD oil penetration into joints by sonophoresis.
Read the detailed description
Materials and Methods:
Inclusion criteria:
- Osteo-arthritis of knee joint diagnosed through X-Ray evaluation
- Moderate or sever level of pain due to knee osteoarthritis and no other known reason
- Male of Female patients of 18 to 85 years old
- Pain interfering with activities of daily life
Exclusion criteria:
- Cancer pain or any other concurrent cancerous condition
- History of Knee replacement surgery in the study joint
- Local infection or any kind of inflammatory or allergic skin lesion
- Rheumatoid arthritis
- Mobility disorders or not being able to walk
Subjects suffering from chronic pain due to osteoarthritis of the knee will be recruited for this study, and randomly assigned to two groups. One-half of these Subjects (Group A) will receive ultrasound therapy as detailed below on the affected joint; the other half (Group B) is a placebo group. Assuming 60% of subjects in Group A show some improvement, as do 30% of patients in Group B, total enrolment of 84 patients (42 per group) will yield statistically significant results (p=0.05; 80% power).
A Study Administrator will assign subjects to a treatment group randomly, and keep this information strictly confidential. Subjects and investigators will be blinded. The Study Administrator will assign each participant a randomly generated Patient ID number to be used in the collection of data.
Subjects will provide in advance written consent to participate in the study, in accordance with Health Canada requirements. Participating subjects will provide baseline pain assessments prior to their first treatment using a 10-point Numeric Pain Scale. They will indicate their current level of pain, and the best and worst pain experienced in the previous 24 hours. An average of these three ratings will be noted. Additionally, participants will complete a Brief Pain Inventory, indicating the location(s) of their pain as well as its impact on general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life.
Group A: The first patient group will receive ultrasound therapy on the affected knee joint, using the CPI-LIPUS Device (Circuit Plus Inc., Richmond Hill, Ontario). This low intensity pulsed ultrasonic system operates at 1 MHz for a fixed time of 5 minutes, with a pulsed repetition of 1 kHz. Its total acoustic power is 6.3 W 5%, equivalent to 1.2 W/cm2 acoustic intensity. (Complete technical specifications of and instructions for CPI-LIPUS are attached as Appendix I.) Ultrasound treatment will be pulsed at 50%.
The head of device will be applied to the most painful area of the knee (typically the medial or lateral upper quadrant) for one cycle of five minutes using ultrasound conductive media providing rotating movements, applying only enough pressure to provide adequate coupling of treatment head and the treatment area.
Group B: Group B will be "treated" with an identical device whose ultrasound emitting capabilities has been nullified. This device appears to operate, including illumination of the operating light. The head of the device will be applied to the most painful area of the knee (typically the medial or lateral upper quadrant) for five minutes exactly in the same manner as the Group A.
Treatment of all patients will take place at Toronto Poly Clinic, Toronto Ontario, a multi-disciplinary clinic focused on the treatment of chronic pain. Lead investigator Dr. Rod is their treating physician. Treatments will be repeated at an interval of seven days. A total of six treatments will be performed. Pain assessments will be conducted prior to each treatment, and at 14 days following the last treatment.
Toronto Poly Clinic follows the College of Physicians and Surgeons of Ontario practice regulations including confidentiality and privacy rules and regulations. Study materials will only have subject/patient ID number.
Participating patients will have free access to their usual analgesic treatments throughout the study. A condition of participation in the trial is the patients' agreement to maintain their current analgesic regimen, without change in medication or dosage.
Once a day, participating subjects will rate their joint pain and ease of use of the joint on 10-point Likert scales. They will also record any use of analgesic medication. These data will be noted in Patient Diaries, whose only identifier will be the Patient ID number for maintaining full confidentiality and privacy.
Data from pain assessments, and from the Patient Diaries, will be analyzed to determine the impact of ultrasound therapy on chronic pain due to osteoarthritis of the knee joint. Statistical significance will be assessed.
Data safety: All study materials, diaries, assessments and clinical notes collectively called data will be kept in secure server of the clinic for electronic data or locked cabinet of a secure area in clinic for paper data documents.
- Conditions
- Osteoarthritis in the Knee
- Being tested
- Low Intensity Ultrasound Therapy, Enhancing CBD oil penetration into joints by sonophresis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Low Intensity Ultrasound TherapyProcedure or surgery
Subjects suffering from chronic pain due to osteoarthritis of the knee will be recruited for this study, and randomly assigned to two groups. One-half of these Subjects (Group A) will receive ultrasound therapy as detailed below on the affected joint; the other half (Group B) is a placebo group.
Enhancing CBD oil penetration into joints by sonophresisOther
High CBD oil will be applied to the affected knee of one-half of the recruited subjects.
| Study group | Role | What they receive |
|---|---|---|
| Group A | Active comparator | The first patient group will receive Low Intensity Ultrasound Therapy on the affected knee joint, using the CPI-LIPUS Device Receives: Procedure: Low Intensity Ultrasound Therapy |
| Group B | Placebo comparator | Will be "treated" with an identical device whose ultrasound emitting capabilities has been nullified. This device appears to operate, including illumination of the operating light. Receives: Procedure: Low Intensity Ultrasound Therapy |
| Group B1 | Active comparator | The first patient group will receive high CBD oil applied topically to the affected knee joint. Receives: Other: Enhancing CBD oil penetration into joints by sonophresis |
| Group B2 | No intervention | This group of patients will not receive high CBD oil to the affected joint. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pain Intensity Measure
Participants who receive treatment using the CPI-LIPUS , a low intensity pulsed ultrasonic device will document any changes to their pain severity on a Brief Pain Inventory numeric scale from 1 to 10, with 1 being no pain, and 10 being the worst pain at each appointment.
Measured: The outcome will be measured over a period of 6 weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Sep 2018
- Study start15 Jun 2019
- Primary completionDec 2019 (estimated)
- Study completionDec 2019 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Osteoarthritis in the KneeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This clinical trial will investigate the safety and efficacy of a new hand-held, low-intensity therapeutic ultrasound (LIPUS) device to treat chronic knee pain in osteoarthritis patients. Osteoarthritis of the knee is painful condition, and a leading cause of disability \[11\]. Two meta-analyses of this application indicate its efficacy in controlling pain \[7,10\]; one in improving function \[10\]. Three randomized, double blind, placebo-controlled studies have been published recently. Two demonstrate the ameliorative effects of low-intensity ultrasound therapy on pain, function and quality of life in patients with knee osteoarthritis \[12,13\]; one showed no significant difference from placebo \[9\]. Significantly, no adverse event was reported in any of these clinical trials. However subjects will have 24 hours phone access and email access to study administrator and study investigator for reporting any type of adverse event and seeking guidance if needed.
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 84 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Dr. Kevin Rod
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Dr. Kevin Rod, Toronto Poly Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03679507
- Sponsor's protocol ID
- TPC-5460-204-0918
- Status last verified
- Sep 2019
- First submitted
- 13 Sep 2018
- Last updated
- 12 Sep 2019
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Sep 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Low Intensity Ultrasound Therapy on Chronic Pain Due to Osteoarthritis of the Knee.
- ClinicalTrials.gov ID
- NCT03679507
- Acronym / sponsor ID
- TPC-5460-204-0918
- Conditions
- Osteoarthritis in the Knee
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 84 participants (estimated)
- Lead sponsor
- Dr. Kevin RodUniversity, hospital or other
- Study start
- 15 Jun 2019 (actual)
- Primary completion
- Dec 2019 (estimated)
- Study completion
- Dec 2019 (estimated)
- First posted
- 20 Sep 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate a new, low intensity ultrasound device in the treatment of chronic pain due to osteoarthritis in the knee.
Enhancing CBD oil penetration into joints by sonophoresis.
Detailed description
Materials and Methods:
Inclusion criteria:
- Osteo-arthritis of knee joint diagnosed through X-Ray evaluation
- Moderate or sever level of pain due to knee osteoarthritis and no other known reason
- Male of Female patients of 18 to 85 years old
- Pain interfering with activities of daily life
Exclusion criteria:
- Cancer pain or any other concurrent cancerous condition
- History of Knee replacement surgery in the study joint
- Local infection or any kind of inflammatory or allergic skin lesion
- Rheumatoid arthritis
- Mobility disorders or not being able to walk
Subjects suffering from chronic pain due to osteoarthritis of the knee will be recruited for this study, and randomly assigned to two groups. One-half of these Subjects (Group A) will receive ultrasound therapy as detailed below on the affected joint; the other half (Group B) is a placebo group. Assuming 60% of subjects in Group A show some improvement, as do 30% of patients in Group B, total enrolment of 84 patients (42 per group) will yield statistically significant results (p=0.05; 80% power).
A Study Administrator will assign subjects to a treatment group randomly, and keep this information strictly confidential. Subjects and investigators will be blinded. The Study Administrator will assign each participant a randomly generated Patient ID number to be used in the collection of data.
Subjects will provide in advance written consent to participate in the study, in accordance with Health Canada requirements. Participating subjects will provide baseline pain assessments prior to their first treatment using a 10-point Numeric Pain Scale. They will indicate their current level of pain, and the best and worst pain experienced in the previous 24 hours. An average of these three ratings will be noted. Additionally, participants will complete a Brief Pain Inventory, indicating the location(s) of their pain as well as its impact on general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life.
Group A: The first patient group will receive ultrasound therapy on the affected knee joint, using the CPI-LIPUS Device (Circuit Plus Inc., Richmond Hill, Ontario). This low intensity pulsed ultrasonic system operates at 1 MHz for a fixed time of 5 minutes, with a pulsed repetition of 1 kHz. Its total acoustic power is 6.3 W 5%, equivalent to 1.2 W/cm2 acoustic intensity. (Complete technical specifications of and instructions for CPI-LIPUS are attached as Appendix I.) Ultrasound treatment will be pulsed at 50%.
The head of device will be applied to the most painful area of the knee (typically the medial or lateral upper quadrant) for one cycle of five minutes using ultrasound conductive media providing rotating movements, applying only enough pressure to provide adequate coupling of treatment head and the treatment area.
Group B: Group B will be "treated" with an identical device whose ultrasound emitting capabilities has been nullified. This device appears to operate, including illumination of the operating light. The head of the device will be applied to the most painful area of the knee (typically the medial or lateral upper quadrant) for five minutes exactly in the same manner as the Group A.
Treatment of all patients will take place at Toronto Poly Clinic, Toronto Ontario, a multi-disciplinary clinic focused on the treatment of chronic pain. Lead investigator Dr. Rod is their treating physician. Treatments will be repeated at an interval of seven days. A total of six treatments will be performed. Pain assessments will be conducted prior to each treatment, and at 14 days following the last treatment.
Toronto Poly Clinic follows the College of Physicians and Surgeons of Ontario practice regulations including confidentiality and privacy rules and regulations. Study materials will only have subject/patient ID number.
Participating patients will have free access to their usual analgesic treatments throughout the study. A condition of participation in the trial is the patients' agreement to maintain their current analgesic regimen, without change in medication or dosage.
Once a day, participating subjects will rate their joint pain and ease of use of the joint on 10-point Likert scales. They will also record any use of analgesic medication. These data will be noted in Patient Diaries, whose only identifier will be the Patient ID number for maintaining full confidentiality and privacy.
Data from pain assessments, and from the Patient Diaries, will be analyzed to determine the impact of ultrasound therapy on chronic pain due to osteoarthritis of the knee joint. Statistical significance will be assessed.
Data safety: All study materials, diaries, assessments and clinical notes collectively called data will be kept in secure server of the clinic for electronic data or locked cabinet of a secure area in clinic for paper data documents.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 4
- Model description
- This clinical trial will investigate the safety and efficacy of a new hand-held, low-intensity therapeutic ultrasound (LIPUS) device to treat chronic knee pain in osteoarthritis patients. Osteoarthritis of the knee is painful condition, and a leading cause of disability [11]. Two meta-analyses of this application indicate its efficacy in controlling pain [7,10]; one in improving function [10]. Three randomized, double blind, placebo-controlled studies have been published recently. Two demonstrate the ameliorative effects of low-intensity ultrasound therapy on pain, function and quality of life in patients with knee osteoarthritis [12,13]; one showed no significant difference from placebo [9]. Significantly, no adverse event was reported in any of these clinical trials. However subjects will have 24 hours phone access and email access to study administrator and study investigator for reporting any type of adverse event and seeking guidance if needed.
| Arm | Type | Receives |
|---|---|---|
| Group A | Active comparator | Procedure: Low Intensity Ultrasound TherapyThe first patient group will receive Low Intensity Ultrasound Therapy on the affected knee joint, using the CPI-LIPUS Device |
| Group B | Placebo comparator | Procedure: Low Intensity Ultrasound TherapyWill be "treated" with an identical device whose ultrasound emitting capabilities has been nullified. This device appears to operate, including illumination of the operating light. |
| Group B1 | Active comparator | Other: Enhancing CBD oil penetration into joints by sonophresisThe first patient group will receive high CBD oil applied topically to the affected knee joint. |
| Group B2 | No intervention | –This group of patients will not receive high CBD oil to the affected joint. |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Osteo-arthritis of knee joint diagnosed through X-Ray evaluation
- Moderate or sever level of pain due to knee osteoarthritis and no other known reason
- Male of Female patients of 18 to 85 years old
- Pain interfering with activities of daily life
Key exclusion criteria (5 listed)
- Cancer pain or any other concurrent cancerous condition
- History of Knee replacement surgery in the study joint
- Local infection or any kind of inflammatory or allergic skin lesion
- Rheumatoid arthritis
- Mobility disorders or not being able to walk
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Low Intensity Ultrasound TherapySubjects suffering from chronic pain due to osteoarthritis of the knee will be recruited for this study, and randomly assigned to two groups. One-half of these Subjects (Group A) will receive ultrasound therapy as detailed below on the affected joint; the other half (Group B) is a placebo group. | Procedure or surgery | Group A, Group B |
| Enhancing CBD oil penetration into joints by sonophresisHigh CBD oil will be applied to the affected knee of one-half of the recruited subjects. | Other | Group B1 |
Primary outcome
Pain Intensity Measure
Time frame: The outcome will be measured over a period of 6 weeks.
Participants who receive treatment using the CPI-LIPUS , a low intensity pulsed ultrasonic device will document any changes to their pain severity on a Brief Pain Inventory numeric scale from 1 to 10, with 1 being no pain, and 10 being the worst pain at each appointment.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Sep 2019.
- Individual participant dataSharing planned: No
Related trials for Osteoarthritis in the Knee
Recruiting
Effect of Anti-inflammatory Diet in Osteoarthritis
Osteoarthritis, Knee
Active, not recruitingPhase 2/3
Single vs Triple Hyaluronic Acid in Knee Osteoarthritis
Osteoarthritis, Knee
Not yet recruiting
The Feasibility of a Virtual/Home-based OA Treatment Program in Older Adults With OA and Multimorbidity
Osteoarthritis of the Knee
RecruitingPhase 3
A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)
Obesity, Overweight
Recruiting
BioPoly® Partial Resurfacing Knee Implant IDE
Knee Pain Chronic, Knee Osteoarthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Low Intensity Ultrasound Therapy and Enhancing CBD oil penetration into joints by sonophresis in people with Osteoarthritis in the Knee, run by Dr. Kevin Rod at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 12 Sep 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pain Intensity Measure (time frame: The outcome will be measured over a period of 6 weeks.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Sep 2019.